The race to deliver safe, effective non-opioid pain therapeutics has never been more urgent – or more achievable. After decades of setbacks, the field is achieving long-awaited progress with recent regulatory approvals from Tonix and Vertex, strategic acquisitions from Eli Lilly, and late-stage successes validating the commercial potential of novel mechanisms.
The Inaugural Non-Opioid Pain Therapeutics Summit is the only meeting dedicated to overcoming the unique scientific and clinical barriers in pain drug development. Discussions will focus on optimizing trial design in chronic pain, advancing mechanism-specific biomarkers, addressing placebo response and patient stratification, and aligning with regulators on validated endpoints.
With case studies spanning NaV inhibitors, novel receptor targets, and first-in-class modalities, the summit provides the scientific depth and clinical perspective required to move non-opioid pain candidates successfully through the pipeline.
Attendees will be learning from companies with approvals such as Tonix, exploring late-stage strategies from innovators like Latigo and Algiax, and uncovering discovery breakthroughs from Nocion and Axonis. Join 70+ discovery, preclinical, translational and clinical industry-based experts driving the future of non-opioid pain therapies across diverse pain indications.
To know more visit: https://ter.li/h7pe87